A 20-year-old college student earned around $110 million after selling his stake in the troubled retailer Bed Bath & Beyond Inc BBBY following the stock's recent rally of more than 339%, according to the Financial Times.
What happened: At a price of roughly $5.20 per share, investor Jake Freeman, a student of mathematics and economics at the University of Southern California, bought nearly 5 million shares of the company in July.
The $25-million stake was purchased through Freeman Capital Management (FCM), a fund registered in Wyoming, according to a Twitter thread exploring the SEC filings and articles of incorporation from the firm. The younger Freeman purchased the 6.2% stake with the help of family and friends, including Jake's uncle Dr. Scott Freeman, a former pharma executive who now works for FCM.
In addition, the elder Freeman co-founded Mind Medicine MNMD and served as its first chief medical officer.
The younger Freeman sold the Bed Bath & Beyond stake on Tuesday when shares closed at a one-month high of $26.93.
Read more: Bed Bath & Beyond Analyst Says Pullback To $2 Likely, Trends At Retailer Remain 'Challenged'
Freeman remarked in the Financial Times story: “I certainly did not expect such a vicious rally upwards. I thought this was going to be a six months plus play — I was really shocked that it went up so fast.”
Why It Matters: The younger Freeman isn’t done yet. He and his uncle sent a scathing letter to the board of directors at MindMed — reminiscent of Ryan Cohen sending a letter to the Bed Bath & Beyond board of directors in March — calling for the board to accept a new strategy put forth by FCM that focuses on the company's core medications, reduces cash consumption and ends an at-the-money equity offering.
Dr. Freeman also offered to join the psychedelics company's board of directors in the letter. Shares of MindMed jumped 58% after the news broke Thursday.
Bed Bath & Beyond shares dropped on Wednesday, ending the day at $23.08. RC Ventures, Cohen's VC fund, announced its intention to sell 9.45 million shares and options via JPMorgan Securities.
Photo via Shutterstock.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.